DMT (N,N-Dimethyltryptamine)

Psychedelicsmoked (vaporized) · inferred

Endogenous tryptamine psychedelic and potent 5-HT2A agonist. When smoked or injected, onset is near-instantaneous with effects lasting ~15-20 minutes due to rapid MAO-mediated metabolism (half-life ~10-12 min). Orally inactive unless combined with an MAO inhibitor (as in ayahuasca). Exhibits biphasic elimination: rapid initial phase (t1/2 ~5-6 min) followed by slower terminal phase (~15 min).

Projected serum levels — 30 mg, as needed (shown daily)

Maintenance schedule: 30 mg as needed (shown daily) (smoked (vaporized)).

Modeled steady state after ~1 days: peak ≈ 12.8 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 30 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category: Psychedelic
Route modeled: Smoked (vaporized)
Model confidence: inferred
Half-life: 10 min
Common dose: 30 mg
Reference dose range: 15–60 mg (single dose)
Suggested cadence: as needed (shown daily)

Documented interactions

danger
1P-LSD (1-Propionyl-LSD) + DMT (N,N-Dimethyltryptamine) Serotonin risk
1P-LSD (1-Propionyl-LSD) and DMT (N,N-Dimethyltryptamine) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
danger
25I-NBOMe + DMT (N,N-Dimethyltryptamine) Serotonin risk
25I-NBOMe and DMT (N,N-Dimethyltryptamine) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
danger
2C-I (2,5-Dimethoxy-4-iodophenethylamine) + DMT (N,N-Dimethyltryptamine) Serotonin risk
2C-I (2,5-Dimethoxy-4-iodophenethylamine) and DMT (N,N-Dimethyltryptamine) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…
danger
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + DMT (N,N-Dimethyltryptamine) CYP inhibition
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) reversible_inhibitor of MAO-A predicted to change DMT (N,N-Dimethyltryptamine) AUC by ~2.97x
danger
3-MeO-PCP (3-Methoxyphencyclidine) + DMT (N,N-Dimethyltryptamine) Serotonin risk
3-MeO-PCP (3-Methoxyphencyclidine) and DMT (N,N-Dimethyltryptamine) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
danger
4-AcO-DMT (Psilacetin) + DMT (N,N-Dimethyltryptamine) Stacked effects
4-AcO-DMT (Psilacetin) and DMT (N,N-Dimethyltryptamine) both push the serotonin 5HT1A, serotonin 5HT2A, and serotonin 5HT2C in the same direction.

Serum checks 128 modeled interaction pairings for dmt (n,n-dimethyltryptamine) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

Pharmacokinetics of N,N-dimethyltryptamine in Humans Good M et al. · European Journal of Drug Metabolism and Pharmacokinetics, 2023 DOI
Characterized IV DMT pharmacokinetics in 24 healthy subjects at 9-21.5 mg doses, finding elimination half-life of 9-12 min with biphasic decline and rapid initial clearance phase of 5-6 min.
Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis Vogt SB et al. · Clinical Pharmacokinetics, 2025 DOI
Systematic review analyzing 13 publications covering eight datasets of DMT pharmacokinetics across multiple routes, establishing consensus PK parameters for clinical development.
Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants Timmermann C et al. · Translational Psychiatry, 2023 DOI
RCT of IV DMT in healthy volunteers documenting rapid onset, dose-dependent subjective effects, and pharmacokinetic profile consistent with very short half-life and rapid clearance.

3 published studies referenced in the app, each with a plain-language summary.